Fast Facts Managing Immune Related Adverse Events In Oncology

Fast Facts: Managing Immune-Related Adverse Events in Oncology, 2nd edition, provides an overview of immuno-oncology and an update on immune checkpoint inhibitors and their associated toxicities, alongside the principles of diagnosing and managing immune-related adverse events, important nursing care considerations and a set of convenient management summaries for quick reference. As such, it is essential reading for all members of the cancer care team. Table of Contents: • Immunotherapy and its side effects: an overview • Gastrointestinal and hepatic adverse events • Dermatologic adverse events • Endocrine-related adverse events • Pulmonary adverse events • Less frequent adverse events • Optimizing patient care and early recognition of irAEs • Management summaries

Immunotherapeutic products, and immune checkpoints inhibitors in particular, are increasingly used in the management of malignancies, both as monotherapies and in combination. Adverse events tend to be mild to moderate, but they can be severe or even life-threatening. Prompt recognition and effective management are vital. 'Fast Facts: Managing Immune-Related Adverse Events' is an accessible overview that brings together clear explanations and management summaries. This highly readable handbook examines the possible effects of immunotherapies on the skin, gastrointestinal tract, liver, endocrine system and lungs, as well as less frequent reactions. Detailed descriptions and evidence-based guidance for practical application make 'Fast Facts: Managing Immunotherapy-Related Adverse Events' an invaluable resource for all healthcare professionals who may encounter patients using immunotherapy, including nurses, who are particularly well placed to identify changes linked to use of immunotherapy, those working in the emergency department and primary care providers. Table of Contents: • Immunotherapy and its side effects: an overview • Gastrointestinal and hepatic adverse events • Dermatologic adverse • Endocrine-related adverse events • Pulmonary adverse events • Less frequent adverse events • Optimizing patient care and early recognition of immune-related adverse events • Management summaries

The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology for decades and need a refresher or you are just starting out and need a crash course, this book provides all you need to know about immuno-oncology, concisely summarized. Table of Contents: • Components of the immune system • How cancers evade the immune system • How cancer immunotherapy works • Clinical use of immune checkpoint inhibitors • The future of immuno-oncology

Written by leading experts, 'Fast Facts: Clinical Trials in Oncology' will enhance the reader’s ability to critically evaluate published evidence. Assuming little or no prior knowledge, the book sets out clearly the fundamental features of clinical trials. The key attributes of Phase I–III trials of pharmaceutical products are described, as are trials of surgical procedures, radiation therapy and advanced therapies. The processes and documentation required to set up and conduct a trial are outlined, and the authors describe how trial data and real-world evidence are used to improve care. Although this concise colorful book focuses on oncology, the principles apply equally to interventions in other areas of practice. It will prove invaluable to medical, pharmaceutical and allied health professionals who want, or need, an overview of how contemporary clinical trials are designed and conducted.

El uso de inmunoterapia para el tratamiento de neoplasias tanto sólidas como hematológicas es extenso. Los inhibidores del punto de control inmunitario en particular han demostrado ser promisorios en el tratamiento del melanoma, cáncer pulmonar no microcítico y otros tipos de cáncer. La mayor parte de los eventos adversos relacionados con el sistema inmunitario asociados con estos fármacos son leves a moderados, pero en ocasiones también se informan eventos adversos graves que ocasionalmente ponen en riesgo la vida. El manejo eficaz de los eventos adversos relacionados con el sistema inmunitario requiere un reconocimiento temprano, así como de la intervención pronta con esteroides, inmunosupresión y/o estrategias inmunomoduladoras apropiadas para el órgano afectado y la gravedad de la toxicidad. También es esencial educar a los pacientes sobre el potencial y el reconocimiento de estos eventos adversos. Con las inmunoterapias volviéndose cada vez más frecuentes y los profesionales de la salud familiarizándose más con los beneficios de combinar estrategias de inmunoterapia, surge una necesidad apremiante de contar con una guía para reconocer y manejar los eventos adversos relacionados con el sistema inmunitario que puedan surgir. Este recurso proporciona una revisión general de inmunooncología y una actualización sobre los inhibidores del punto de control inmunitario y sus toxicidades relacionadas, junto con los principios de diagnóstico y manejo de los eventos adversos relacionados con el sistema inmunitario, consideraciones importantes sobre el cuidado de enfermería y una serie de resúmenes de manejo convenientes para referencia rápida. Como tal, es una lectura esencial para todos los miembros del equipo de atención oncológica. Indice: • Inmunoterapia y sus efectos secundarios: una revisión general • Eventos adversos gastrointestinales y hepáticos • Eventos adversos dermatológicos • Eventos adversos relacionados con el sistema endocrino • Eventos adversos pulmonares • Eventos adversos menos frecuentes • Optimización de la atención al paciente y reconocimiento temprano de eventos adversos relacionados con el sistema inmunitario • Resúmenes de manejo

Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy

The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.